Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- Editor’s Pick: Five Healthcare News Headlines for August 25 – September 5
September 8, 2014
- Two Female Lawmakers Named New Senior Vice Health Ministers
September 8, 2014
- PAFSC’s Second Committee Backs Approval of Nobelpharma’s Anticancer Drug, MSD’s Hepatitis C Treatment
September 8, 2014
- PAFSC’s First Committee Supports Approval of Lixiana’s Additional Indications
September 5, 2014
- New Health Minister Plays it Safe, Promises to Follow Cabinet Decision on NHI Price Revision Frequency
September 5, 2014
- Industry on Alert as Reformist Shiozaki Tapped as New Health Minister
September 4, 2014
- PFSB Issues Notification on Submission of Package Inserts Under New Act
September 4, 2014
- LDP’s Niwa Says Treatment of Post-HPV Vaccine Adverse Reactions Top Priority
September 3, 2014
- MHLW to Consider Another Punishment or Action against Novartis Pharma: Minister
September 3, 2014
- Yasuhisa Shiozaki Tapped as New Health Minister
September 3, 2014
- MHLW Will Discuss Freezing NHI Prices of Essential Drugs if Industry Requests It: MHLW Official Nakai
September 3, 2014
- MOF Official Unami Urges Full-Scale NHI Price Revision upon Next Sales Tax Hike
September 2, 2014
- METI to Request 20% Increase in Budget for Promotion of Science and Technology: FY2015 Budget Request
September 2, 2014
- MHLW to Reinforce Follow-Up Surveys on HPV Vaccine Recipients
September 1, 2014
- MHLW Prods Univ. of Tokyo to Set Up Third-Party Panel over J-ADNI
September 1, 2014
- MHLW Notifies Prefectures of RMP Submissions for Generics
August 29, 2014
- New Chuikyo Rep Abe Credits Key Premium for Accelerating Drug Development
August 29, 2014
- MHLW Notifies Health Professionals of Revised Package Insert for Simeprevir
August 28, 2014
- Chuikyo Grants Unprecedented 60% Premium to Ono’s Opdivo
August 28, 2014
- MHLW Calls for Maintenance of Current R&D Tax Credit Limit
August 27, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…